Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

被引：2
|
作者：
Desai, Jayesh
Voskoboynik, Mark
Markman, Ben
Hou, Jeannie
Zeng, Dewan
Meniawy, Tarek
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Nucleus Network, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Monash Univ, Melbourne, Vic, Australia
[6] BeiGene USA Inc, Emeryville, CA USA
[7] Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS3113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3113
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
    Huang, Jing
    Mo, Hongnan
    Wu, Dawei
    Chen, Xuelian
    Ma, Lanying
    Lan, Bo
    Qu, Dong
    Yang, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.
    Oh, Do-Youn
    Park, John J.
    Lee, Keun Wook
    Kim, Seung Tae
    Sriuranpong, Virote
    Rha, Sun Young
    Yoo, Changhoon
    Keam, Bhumsuk
    Sabanathan, Dhanusha
    Kim, Se Hyun
    Park, Joon Oh
    Parinyanitikul, Napa
    Kim, Min Hwan
    Kim, Kyu-Pyo
    Kim, Myungsuk
    Yoon, Jaebong
    Lee, Han Seung
    Ock, Chan-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
    Amita Patnaik
    Glen J. Weiss
    Drew W. Rasco
    Lisa Blaydorn
    Amy Mirabella
    Murali Beeram
    Wei Guo
    Sharon Lu
    Hadi Danaee
    Kristen McEachern
    Ellie Im
    Jasgit C. Sachdev
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
  • [24] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
    Keam, Bhumsuk
    Kim, Tae Min
    Oh, Do-Youn
    Ock, Chan-Young
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Song, Yun Jeong
    Park, Young Suk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [25] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
    Naing, Aung
    Infante, Jeffrey
    Goel, Sanjay
    Burris, Howard
    Black, Chelsea
    Marshall, Shannon
    Achour, Ikbel
    Barbee, Susannah
    May, Rena
    Morehouse, Chris
    Pollizzi, Kristen
    Song, Xuyang
    Steele, Keith
    Elgeioushi, Nairouz
    Walcott, Farzana
    Karakunnel, Joyson
    LoRusso, Patricia
    Weise, Amy
    Eder, Joseph
    Curti, Brendan
    Oberst, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [26] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [28] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
    O'Neil, Bert H.
    Wallmark, John M.
    Lorente, David
    Elez, Elena
    Raimbourg, Judith
    Gomez-Roca, Carlos
    Ejadi, Samuel
    Piha-Paul, Sarina A.
    Stein, Mark N.
    Razak, Albiruni R. Abdul
    Dotti, Katia
    Santoro, Armando
    Cohen, Roger B.
    Gould, Marlena
    Saraf, Sanatan
    Stein, Karen
    Han, Sae-Won
    PLOS ONE, 2017, 12 (12):
12345